This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Stanford Graduate School of Business (USA)
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74
-
Tim Harkness: Starting Over - Teaching Note
Robert Siegel, Jessica MorganTeaching Note SGSB-E564TN-EEntrepreneurshipThis case profiles the journey of protagonist Tim Harkness through his many entrepreneurial pursuits. It chronicles his early career and how a bout of serendipity landed him a job in the life sciences tools industry. From there, Harkness went on to lead another life sciences tools company, and transformed the company from an under-performing venture-backed start-up to a profitable multi-product firm. After four acquisitions, a failed sales p...Starting at €0.00
-
ComplexAminos
Robert Siegel, Jessica MorganCase SGSB-E565-EEntrepreneurshipThis case explores the transformation of a company, ComplexAminos, from a failing start-up to a successful organization preparing for a liquidity event. After conducting a six-year turnaround strategy, the CEO needed to decide whether the company should go public or be sold. During the turnaround, the company adopted a roll-up strategy to grow quickly. This case explores such issues as when roll-ups are appropriate and how the CEO gained the f...Starting at €8.20
-
Tim Harkness: Starting Over
Robert Siegel, Jessica MorganCase SGSB-E564-EEntrepreneurshipThis case profiles the journey of protagonist Tim Harkness through his many entrepreneurial pursuits. It chronicles his early career and how a bout of serendipity landed him a job in the life sciences tools industry. From there, Harkness went on to lead another life sciences tools company, and transformed the company from an under-performing venture-backed start-up to a profitable multi-product firm. After four acquisitions, a failed sales p...Starting at €8.20
-
Invitrogen/Life Technologies (C): The "Best Owner" of the Asset
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209C-EStrategyThis short case discusses the process of Life Technologies’ acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.Starting at €5.74
-
ComplexAminos - Teaching Note
Robert Siegel, Jessica MorganTeaching Note SGSB-E565TN-EEntrepreneurshipThis case explores the transformation of a company, ComplexAminos, from a failing start-up to a successful organization preparing for a liquidity event. After conducting a six-year turnaround strategy, the CEO needed to decide whether the company should go public or be sold. During the turnaround, the company adopted a roll-up strategy to grow quickly. This case explores such issues as when roll-ups are appropriate and how the CEO gained the f...Starting at €0.00